Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis

Osteoporosis International

Volumn 11, Issue 1, 2000, Pages 83-91

  Reginster, J Y ^a   Minne, H W ^b   Sorensen, O H ^c   Hooper, M ^d   Roux, C ^e   Brandi, M L ^f   Lund, B ^g   Ethgen, D ^h   Pack, S ^h   Roumagnac, I ^h   Eastell, R ⁱ  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b Clinic for Metabolic Bone Disease   (Germany)

^c Copenhagen Municipal Hospital ^*  (Denmark)

^d UNIVERSITY OF SYDNEY   (Australia)

^e René Descartes University ^*  (France)

^f UNIVERSITY OF FLORENCE   (Italy)

^g Procter and Gamble Pharmaceuticals ^*

^h UNIVERSITY OF SHEFFIELD   (United Kingdom)

ⁱ NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonates; Bone mineral density; Osteoporosis; Postmenopausal women; Risedronate; Vertebral fracture

Indexed keywords

CALCIUM; PLACEBO; RISEDRONIC ACID; VITAMIN D;

ADULT; AGED; ARTICLE; AUSTRALIA; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DUAL ENERGY X RAY ABSORPTIOMETRY; EUROPE; FEMALE; FRACTURE; GASTROINTESTINAL SYMPTOM; HIP; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL; RISK; SPINE; VERTEBRA FRACTURE;

AGED; AGED, 80 AND OVER; ALGORITHMS; AUSTRALIA; BONE DENSITY; CALCIUM CHANNEL BLOCKERS; DENSITOMETRY, X-RAY; DOUBLE-BLIND METHOD; ETIDRONIC ACID; EUROPE; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 12944291524     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001980050010     Document Type: Article

References (32)

1. Dolan P, Torgerson DJ. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 1998;8:611-7.
2. Cauley JA, Seeley DG, Ensrud K, Ettinger B, Black D, Cummings SR. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1995;122:9-16.
3. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1-9.
4. Harris ST, Watts NB, Jackson RD, et al. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med 1993;95:557-67.
5. Liberman UA, Weiss SR, Bröil J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43.
6. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
7. Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharm 1998;4:488-92.
8. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996;335:1016-21.
9. Maconi G, Porro GB. Multiple ulcerative esophagitis caused by alendronate. Am J Gastroenterol 1995;90:1889-90.
10. McClung M, Bensen W, Bolognese M, et al. Risedronate increases bone mineral density at the hip, spine, and radius in postmenopausal women with low bone mass. [abstract]. Osteoporos Int 1998:8(Suppl3):111.
11. Eastell R, Watts N, McClung M, et al. Integrated safety analysis of risedroante in postmenopausal women [abstract]. Presented at the 81st Annual Meeting of the Endocrine Society, San Diego, CA, June 12-15, 1999.
12. Miller PD, Brown JP, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A comparative trial of risedronate versus etidronate in the treatment of patients with Paget's disease of bone. Am J Med 1999; 106:513-20.
13. Hosking DJ, Eusebio RA, Chines AA. Paget's disease of bone: reduction of disease activity with oral risedronate. Bone 1998;22:51-5.
14. Roux C, Ravaud P, Cohen-Solal M, et al. Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 1994;15:41-9.
15. Cohen-Solal ME, Roux C, Valentin-Opran A, Dougados M, Amor B, de Vernejoul MC. Histomorphometric effect of six month treatment with oral risedronate in patients with multiple myeloma. Bone 1993;14:505-9.
16. Reasner CA, Stone MD, Hosking DJ, Ballah A, Mundy GR. Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate. J Clin Endocrinol Metab 1993;77:1067-71.
17. Melton LJ III, Lane AW, Cooper C, Eastell R, O'Fallon WM, Riggs BL. Prevalence and incidence of vertebral deformities. Osteoporos Int 1993;3:113-9.
18. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137-48.
19. England TE, Samsoondar J, Maw G. Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase. Clin Biochem 1994;27:187-9.
20. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
21. Genant HK, Grampp S, Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibration results. J Bone Miner Res 1994;9:1503-14.
22. Steiger P. Standardization of postero-anterior (PA) spine BMD measurements by DXA. Committee for Standards in DXA. Bone 1995;17:435.
23. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45.
24. Wilkin TJ. Changing perceptions in osteoporosis. BMJ 1999; 318:862-4.
25. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 1998;338:736-46.
26. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF. The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 1995;10:211-21.
27. Forwood MR, Burr DB, Takano Y, Eastman DF, Smith PN, Schwardt JD. Risedronate treatment does not increase microdamage in the canine femoral neck. Bone 1995;16:643-50.
28. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized, controlled trial. JAMA 1999;282:1344-52.
29. van der Wielen RP, Lowik MR, van den Berg H, et al. Serum vitamin D concentrations among elderly people in Europe. Lancet 1995;346:207-10.
30. Mackay FJ, Wilton LV, Pearce GL, Freemantle SN, Mann RD. United Kingdom experience with alendronate and oesophageal reactions. Br J Gen Pract 1998;48:1161-2.
31. Spivacow FR, Zanchetta JR, Kerzberg EM, Frigerl A, Flasche R, Roldan E. Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseases. Curr Ther Res 1996;57:123-30.
32. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: an unrecognized problem in gastrointestinal tolerability. Osteoporos Int 1994;4:320-2.